Selected research
Industry Research
Etodolac Industry Research Report 2026
Market perspective
The global Etodolac market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Etodolac is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Etodolac is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Etodolac is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Etodolac include Teva, Taro Pharmaceuticals, Physicians Total Care, PD-Rx Pharmaceuticals, Nucare Pharmaceuticals, Genpharm Ulc, Eon Labs, Blenheim Pharmacal and Apotex, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Etodolac market in terms of revenue (US$ million) and, where applicable, sales volume (k pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Etodolac Market by Company
Teva
Taro Pharmaceuticals
Physicians Total Care
PD-Rx Pharmaceuticals
Nucare Pharmaceuticals
Genpharm Ulc
Eon Labs
Blenheim Pharmacal
Apotex
Amneal Pharmaceuticals
Actavis Elizabeth
Etodolac Segment by Type
Tablets
Capsules
Etodolac Segment by Application
Mild to Moderate Pain
Rheumatoid Arthritis
Osteoarthritis
Others
Etodolac Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Etodolac market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Etodolac and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Etodolac.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Etodolac manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Etodolac by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Etodolac in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tablets
- Capsules
Applications
- Mild to Moderate Pain
- Rheumatoid Arthritis
- Osteoarthritis
- Others
Companies covered
- Teva
- Taro Pharmaceuticals
- Physicians Total Care
- PD-Rx Pharmaceuticals
- Nucare Pharmaceuticals
- Genpharm Ulc
- Eon Labs
- Blenheim Pharmacal
- Apotex
- Amneal Pharmaceuticals
- Actavis Elizabeth
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Etodolac Market Size (2021-2032)
- 2.2.2 Global Etodolac Sales (2021-2032)
- 2.2.3 Global Etodolac Market Average Price (2021-2032)
- 2.3 Etodolac by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Tablets
- 2.3.3 Capsules
- 2.4 Etodolac by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Mild to Moderate Pain
- 2.4.3 Rheumatoid Arthritis
- 2.4.4 Osteoarthritis
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Etodolac Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Etodolac Sales (k pcs) of Manufacturers (2021-2026)
- 3.3 Global Etodolac Revenue of Manufacturers (2021-2026)
- 3.4 Global Etodolac Average Price by Manufacturers (2021-2026)
- 3.5 Global Etodolac Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Etodolac, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Etodolac, Product Type & Application
- 3.8 Global Manufacturers of Etodolac, Established Date
- 3.9 Global Etodolac Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva Etodolac Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Etodolac Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 Taro Pharmaceuticals
- 4.2.1 Taro Pharmaceuticals Company Information
- 4.2.2 Taro Pharmaceuticals Business Overview
- 4.2.3 Taro Pharmaceuticals Etodolac Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Taro Pharmaceuticals Etodolac Product Portfolio
- 4.2.5 Taro Pharmaceuticals Recent Developments
- 4.3 Physicians Total Care
- 4.3.1 Physicians Total Care Company Information
- 4.3.2 Physicians Total Care Business Overview
- 4.3.3 Physicians Total Care Etodolac Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Physicians Total Care Etodolac Product Portfolio
- 4.3.5 Physicians Total Care Recent Developments
- 4.4 PD-Rx Pharmaceuticals
- 4.4.1 PD-Rx Pharmaceuticals Company Information
- 4.4.2 PD-Rx Pharmaceuticals Business Overview
- 4.4.3 PD-Rx Pharmaceuticals Etodolac Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 PD-Rx Pharmaceuticals Etodolac Product Portfolio
- 4.4.5 PD-Rx Pharmaceuticals Recent Developments
- 4.5 Nucare Pharmaceuticals
- 4.5.1 Nucare Pharmaceuticals Company Information
- 4.5.2 Nucare Pharmaceuticals Business Overview
- 4.5.3 Nucare Pharmaceuticals Etodolac Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Nucare Pharmaceuticals Etodolac Product Portfolio
- 4.5.5 Nucare Pharmaceuticals Recent Developments
- 4.6 Genpharm Ulc
- 4.6.1 Genpharm Ulc Company Information
- 4.6.2 Genpharm Ulc Business Overview
- 4.6.3 Genpharm Ulc Etodolac Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Genpharm Ulc Etodolac Product Portfolio
- 4.6.5 Genpharm Ulc Recent Developments
- 4.7 Eon Labs
- 4.7.1 Eon Labs Company Information
- 4.7.2 Eon Labs Business Overview
- 4.7.3 Eon Labs Etodolac Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Eon Labs Etodolac Product Portfolio
- 4.7.5 Eon Labs Recent Developments
- 4.8 Blenheim Pharmacal
- 4.8.1 Blenheim Pharmacal Company Information
- 4.8.2 Blenheim Pharmacal Business Overview
- 4.8.3 Blenheim Pharmacal Etodolac Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Blenheim Pharmacal Etodolac Product Portfolio
- 4.8.5 Blenheim Pharmacal Recent Developments
- 4.9 Apotex
- 4.9.1 Apotex Company Information
- 4.9.2 Apotex Business Overview
- 4.9.3 Apotex Etodolac Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Apotex Etodolac Product Portfolio
- 4.9.5 Apotex Recent Developments
- 4.10 Amneal Pharmaceuticals
- 4.10.1 Amneal Pharmaceuticals Company Information
- 4.10.2 Amneal Pharmaceuticals Business Overview
- 4.10.3 Amneal Pharmaceuticals Etodolac Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Amneal Pharmaceuticals Etodolac Product Portfolio
- 4.10.5 Amneal Pharmaceuticals Recent Developments
- 4.11 Actavis Elizabeth
- 4.11.1 Actavis Elizabeth Company Information
- 4.11.2 Actavis Elizabeth Business Overview
- 4.11.3 Actavis Elizabeth Etodolac Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Actavis Elizabeth Etodolac Product Portfolio
- 4.11.5 Actavis Elizabeth Recent Developments
5 Global Etodolac Market Scenario by Region
- 5.1 Global Etodolac Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Etodolac Sales by Region: 2021-2032
- 5.2.1 Global Etodolac Sales by Region: 2021-2026
- 5.2.2 Global Etodolac Sales by Region: 2027-2032
- 5.3 Global Etodolac Revenue by Region: 2021-2032
- 5.3.1 Global Etodolac Revenue by Region: 2021-2026
- 5.3.2 Global Etodolac Revenue by Region: 2027-2032
- 5.4 North America Etodolac Market Facts & Figures by Country
- 5.4.1 North America Etodolac Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Etodolac Sales by Country (2021-2032)
- 5.4.3 North America Etodolac Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Etodolac Market Facts & Figures by Country
- 5.5.1 Europe Etodolac Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Etodolac Sales by Country (2021-2032)
- 5.5.3 Europe Etodolac Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Etodolac Market Facts & Figures by Country
- 5.6.1 Asia Pacific Etodolac Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Etodolac Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Etodolac Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Etodolac Market Facts & Figures by Country
- 5.7.1 South America Etodolac Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Etodolac Sales by Country (2021-2032)
- 5.7.3 South America Etodolac Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Etodolac Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Etodolac Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Etodolac Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Etodolac Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Etodolac Sales by Type (2021-2032)
- 6.1.1 Global Etodolac Sales by Type (2021-2032) & (k pcs)
- 6.1.2 Global Etodolac Sales Market Share by Type (2021-2032)
- 6.2 Global Etodolac Revenue by Type (2021-2032)
- 6.2.1 Global Etodolac Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Etodolac Revenue Market Share by Type (2021-2032)
- 6.3 Global Etodolac Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Etodolac Sales by Application (2021-2032)
- 7.1.1 Global Etodolac Sales by Application (2021-2032) & (k pcs)
- 7.1.2 Global Etodolac Sales Market Share by Application (2021-2032)
- 7.2 Global Etodolac Revenue by Application (2021-2032)
- 7.2.1 Global Etodolac Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Etodolac Revenue Market Share by Application (2021-2032)
- 7.3 Global Etodolac Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Etodolac Value Chain Analysis
- 8.1.1 Etodolac Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Etodolac Production Mode & Process
- 8.2 Etodolac Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Etodolac Distributors
- 8.2.3 Etodolac Customers
9 Global Etodolac Analyzing Market Dynamics
- 9.1 Etodolac Industry Trends
- 9.2 Etodolac Industry Drivers
- 9.3 Etodolac Industry Opportunities and Challenges
- 9.4 Etodolac Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst